Ferozsons Laboratories (KAR:FEROZ) Cyclically Adjusted Revenue per Share: ₨278.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:FEROZ Ferozsons Laboratories Ltd KAR:FEROZ
70 GF Score
Price ₨369.88
GF Value ₨428.45
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Ferozsons Laboratories Cyclically Adjusted Revenue per Share?

Ferozsons Laboratories KAR:FEROZ +1.58% 70 Cyclically Adjusted Revenue per Share is ₨278.29 as of Mar. 2026. GuruFocus rates KAR:FEROZ with a GF Score™ of 70/100 and a GF Value™ of ₨428.45 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ferozsons Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₨127.695. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₨278.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ferozsons Laboratories's average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-21), Ferozsons Laboratories's current stock price is ₨369.88. Ferozsons Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₨278.29. Ferozsons Laboratories's Cyclically Adjusted PS Ratio of today is 1.33.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Ferozsons Laboratories was 1.66. The lowest was 0.71. And the median was 1.32.


Ferozsons Laboratories  (KAR:FEROZ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ferozsons Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=369.88/278.29
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Ferozsons Laboratories was 1.66. The lowest was 0.71. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ferozsons Laboratories Cyclically Adjusted Revenue per Share Related Terms


Ferozsons Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ferozsons Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ferozsons Laboratories Cyclically Adjusted Revenue per Share Chart

Ferozsons Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 227.53 259.67

Ferozsons Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.51 259.67 265.64 269.55 278.29

KAR:FEROZ vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ferozsons Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ferozsons Laboratories's Cyclically Adjusted PS Ratio falls into.


KAR:FEROZ
70GF Score
Ferozsons Laboratories Ltd KAR:FEROZ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ferozsons Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ferozsons Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=127.695/330.2130*330.2130
=127.695

Current CPI (Mar. 2026) = 330.2130.

Ferozsons Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 45.024 241.018 61.686
201609 30.660 241.428 41.935
201612 30.719 241.432 42.015
201703 24.022 243.801 32.536
201706 29.731 244.955 40.079
201709 23.920 246.819 32.002
201712 33.425 246.524 44.772
201803 30.250 249.554 40.027
201806 27.202 251.989 35.646
201809 27.895 252.439 36.489
201812 33.383 251.233 43.878
201903 32.036 254.202 41.615
201906 40.049 256.143 51.630
201909 30.784 256.759 39.591
201912 35.035 256.974 45.020
202003 40.919 258.115 52.349
202006 36.205 257.797 46.375
202009 34.680 260.280 43.998
202012 50.290 260.474 63.755
202103 53.989 264.877 67.306
202106 65.288 271.696 79.350
202109 51.144 274.310 61.567
202112 49.971 278.802 59.186
202203 58.751 287.504 67.479
202206 54.686 296.311 60.943
202209 59.128 296.808 65.783
202212 61.586 296.797 68.520
202303 72.289 301.836 79.085
202306 71.062 305.109 76.909
202309 101.834 307.789 109.253
202312 88.886 306.746 95.686
202403 86.084 312.332 91.012
202406 87.652 314.175 92.126
202409 104.186 315.301 109.113
202412 108.798 315.605 113.834
202503 117.171 319.799 120.987
202506 103.639 322.561 106.098
202509 136.607 324.800 138.884
202512 153.774 324.054 156.697
202603 127.695 330.213 127.695

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₨278.29 mean?
Ferozsons Laboratories (KAR:FEROZ) has a Cyclically Adjusted Revenue per Share of ₨278.29 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ferozsons Laboratories and its competitors.
Is Ferozsons Laboratories' Cyclically Adjusted Revenue per Share too high?
Ferozsons Laboratories' current Cyclically Adjusted Revenue per Share is ₨278.29. Overall, Ferozsons Laboratories has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Ferozsons Laboratories' Cyclically Adjusted Revenue per Share of ₨278.29 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ferozsons Laboratories and its competitors. Ferozsons Laboratories's current Cyclically Adjusted Revenue per Share is ₨278.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Modestly Undervalued. The stock's GF Value™ is ₨428.45, compared to a current price of ₨369.88 — trading 13.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₨278.29. Ferozsons Laboratories' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current Cyclically Adjusted Revenue per Share is ₨278.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?

Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued. The current stock price of ₨369.88 is trading 13.7% below its estimated GF Value™ of ₨428.45. GuruFocus considers Ferozsons Laboratories to be Modestly Undervalued.

Key valuation signals for KAR:FEROZ:

  • Cyclically Adjusted Revenue per Share: ₨278.29
  • GF Value™: ₨428.45 vs. price of ₨369.88 (13.7% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ferozsons Laboratories Business Description

Address 5 K.M Sunder Raiwind Road, Lahore, PB, PAK
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
70GF Score

Get the complete analysis for KAR:FEROZ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨369.88
Price
₨428.45
GF Value